Autogenous Sticky Bone Plus Platelet-rich Fibrin Membrane Versus Xenograft With Collagen Membrane for Posterior Atrophic Mandible
Autogenous Sticky Bone Plus Platelet-rich Fibrin Membrane Versus Xenograft With Collagen Membrane for Treatment of Posterior Atrophic Mandible (A Randomized Controlled Clinical Trial)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Mohamed Essam, BDS
- Phone Number: 01225710437
- Email: mohamedessam2363@gmail.com
Study Locations
-
-
Azarita
-
Alexandria, Azarita, Egypt, 00203
- Outpatient Clinic of Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Alexandria University, Egypt
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with missing posterior mandibular teeth.
- Horizontal bone defect with width < 5.5 mm.
- Adequate zone of keratinized tissue
Exclusion Criteria:
- Presence of infection or periapical lesions in adjacent teeth.
- Medically compromised patients with a condition that affects the procedure.
- Insufficient inter-arch distance.
- Bruxism or clenching.
- Alcoholism.
- Heavy Smokers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control Group
|
Patients in this group will be treated using a xenograft with a collagen membrane.
|
|
Experimental: Test Group
|
Patients in this group will be treated using autogenous sticky bone with PRF membrane.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in implant stability
Time Frame: up to 6 months
|
Implant stability will be recorded immediately after placement (1ry stability) and after 6 months (2ry stability ) by using osstell device.
The result is presented in form of ISQ value from 1 to 100, the higher the ISQ the higher the stability of implant
|
up to 6 months
|
|
change in bucco-lingual bone thickness
Time Frame: up to 6 months
|
All participants in the study will be advised to undergo CBCT before implant placement to measure bucco-lingual bone thickness, and again 7 days postoperatively and 6 months after implant placement to assess the following.
|
up to 6 months
|
|
change in marginal bone level
Time Frame: up to 9 months
|
At buccal, lingual, mesial, and distal sites will be evaluated radiographically from the shoulder of the implant to the alveolar crest.
The mean marginal bone loss after the placement of implants will be calculated by subtracting baseline value from the values obtained at 6 and 9 months post implant placement
|
up to 9 months
|
|
change in ridge width
Time Frame: up to 6 months
|
Will be measured immediately and after 6 months, bone width will be measured for each implant at three levels (2, 5, and 10 mm from the alveolar crest) and the mean will be calculated for each implant at each time interval.
|
up to 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
change in pain scores
Time Frame: up to 7 days
|
Pain will be assessed for 7 days postoperatively using 10-point visual analouge scale (VAS).
(0-1=None, 2-4=mild, 5-7=moderate, 8-10=severe ).
|
up to 7 days
|
|
change in edema scores
Time Frame: up to 7 days
|
Edema will be assessed by a descriptive 4-point scale immediately post-operative, and at the 2nd,3rd,7th days postoperatively.
Measured as follows: No inflammation = none.
Intra oral swelling confined to the surgical field = mild.
Extra oral swelling in the surgical zone =moderate.
Extra oral swelling spreading beyond the surgical zone =intense.
|
up to 7 days
|
|
change in bone density
Time Frame: up to 6 months
|
Will be measured at 6 points around the implant and a mean value will be calculated
|
up to 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1368-07/2026
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.